一种非peptidomimetic HIV 蛋白酶抑制剂的临床前表征,具有改善的代谢稳定性
Andrew Mulato1, Eric Lansdon2, Ron Aoyama3
1Department of Virology, Gilead Sciences, Foster City, California, USA.
Antimicrobial agents and chemotherapy
|February 21, 2024
概括
一种新的HIV蛋白酶抑制剂GS-9770显示出潜在的无增强性,每天一次的口服治疗. 这种试验性药物具有强烈的活性,并改善了对HIV-1的抗药性,从而有可能减少药物相互作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 病毒学 病毒学
- 药物开发 药物开发
背景情况:
- 蛋白酶抑制剂 (PI) 对于HIV-1治疗至关重要,因为其具有较高的抗药性障碍.
- 目前的PIs如阿塔萨纳维尔和达鲁纳维尔需要增强剂,导致药物相互作用.
研究的目的:
- 为了介绍GS-9770,一个新的非peptidomimetic艾滋病毒PI.
- 为了评估其未增强的,每天一次口服剂量的潜力.
主要方法:
- 评估了对HIV-1蛋白酶的抑制活性和选择性.
- 在细胞培养和针对各种亚型中评估了抗HIV-1功效.
- 对患者衍生和抗药性HIV-1分离体进行了耐药性检测.
主要成果:
- GS-9770显示出对HIV-1蛋白酶的强烈抑制和高选择性.
- 在人类初级细胞中实现了纳米分子抗HIV-1功效.
- 在选择实验中显示出更好的耐药性概况,并防止了变种的出现.
结论:
- GS-9770 是一种强效的非模仿性HIVPI,具有不增强性口服的潜力.
- 它可能会在HIV治疗中克服对药物动力学增强剂的需求.
- 临床前数据支持GS-9770的发展,作为每天一次的口服HIV治疗.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...


